Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Taner, Korkmaz"'
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment
Externí odkaz:
https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f
Autor:
Cihan Uras, Neslihan Cabioglu, Fatma Tokat, Ozlem Er, Halil Kara, Taner Korkmaz, Nuran Bese, Umit Ince
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Recent studies have shown a lower likelihood of locoregional recurrences in patients with a low 21-gene recurrence score (RS). In this single-institution study, we investigated whether there are any associations between different
Externí odkaz:
https://doaj.org/article/92f7149da3064caa9a1b866aeaf705c5
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzafer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/62814a4471cb45089f6723c0cccc8157
Autor:
Nilgün Güldoğan, Gül Esen İçten, Fatma Tokat, Burçin Tutar, Halil Kara, Taner Korkmaz, Başak Oyan Uluç, Gökhan Demir
Publikováno v:
European Journal of Breast Health, Vol 17, Iss 2, Pp 200-205 (2021)
Despite the high prevalence of lung cancer among other primary tumors, metastasis of this particular malignancy in the breast is very rare. We report three new cases of lung cancer with breast metastases and discuss radiological and clinical findings
Externí odkaz:
https://doaj.org/article/e07f2d825157491aaacdaddc359f54c0
Autor:
Atakan Demir, Nil Molinas Mandel, Semra Paydas, Gökhan Demir, Özlem Er, Nazım Serdal Turhal, Sevil Bavbek, Yeşim Eralp, Pınar Mualla Saip, Emine Nilüfer Güler, Adnan Aydıner, Başak Oyan Uluç, Sadettin Kılıçkap, Necdet Üskent, Nuri Karadurmuş, Mehmet Ali Kaplan, Mustafa Teoman Yanmaz, Hacer Demir, Özkan Alan, Taner Korkmaz, Polat Olgun, Özlem Sönmez Uysal, Kadri Altundağ, Şeyda Gündüz, Meral Günaldı, Murat Sarı, İsmail Beypınar, Gül Başaran
Publikováno v:
Balkan Medical Journal, Vol 37, Iss 2, Pp 104-107 (2020)
Background:The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6
Externí odkaz:
https://doaj.org/article/04ceb2349b6c44ffbafb27dfc640256d
Autor:
Cihan Uras, Neslihan Cabıoğlu, Fatma Tokat, Halil Kara, Ozlem ER, Taner Korkmaz, Nuran Bese, Umit Ince
Publikováno v:
Cancer Research. 83:P2-11
Background: Recent studies have shown a lower likelihood of locoregional recurrences in patients with low 21-gene recurrence score (RS). In this single institutional study, we investigated any associations between different cut-off values of 21-gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::936cbc5aa92e355ae5206e313cb318f4
https://doi.org/10.1158/1538-7445.sabcs22-p2-11-31
https://doi.org/10.1158/1538-7445.sabcs22-p2-11-31
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Publikováno v:
Future Oncology. 18:2573-2582
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043d1a22a8f3e83e986a7039a57bac7a
https://doi.org/10.2217/fon-2022-0083
https://doi.org/10.2217/fon-2022-0083
Autor:
Yeşim ERALP, İzzet DOĞAN, Sercan Aksoy, Burcu ÇAKAR, Gül BAŞARAN, Özlem ERCELEP, Nil MOLİNAS MANDEL, Taner KORKMAZ, Erhan GÖKMEN, Adnan AYDINER, Pınar SAİP
Publikováno v:
Cancer Research. 83:P3-02
Background: Although HER2 is an aggressive subtype of BC, the outcomes have improved over the past two decades due to advances in targeted therapies. Here, we present data of HER2-positive subset from the multicenter registry study of the Turkish Onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f42d288597a877ba9328aed287ae43a1
https://doi.org/10.1158/1538-7445.sabcs22-p3-02-06
https://doi.org/10.1158/1538-7445.sabcs22-p3-02-06
Autor:
Erhan Gokmen, Ozkan Alan, Gul Basaran, Serdar Turhal, Ozgur Tanriverdi, Yesim Eralp, Burcak Karaca, Semra Paydas, Fatma Paksoy Turkoz, Burcu Çakar, Sevgi Topcu, Gulhan Ipek Deniz, Bulent Karabulut, Seyda Gunduz, Osman Kostek, Taner Korkmaz, Umut Demirci, Sema Sezgin Goksu
Publikováno v:
Cancer Research. 80:P5-11
Background: Ribociclib combined with endocrine therapy (ET) have demonstrated efficacy in patients with hormone receptor (HR) positive advanced breast cancer (ABC) who experienced progression during prior ET. However, there are scarce data chemo-endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a18cbf7d094af11a0281bc8c35ee0c0
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e995dc25bd5d60e4fc0b04e58d82c9ea
https://doi.org/10.1080/07357907.2021.1933011
https://doi.org/10.1080/07357907.2021.1933011